Lilly Asia Ventures, a regional corporate venturing subsidiary of pharmaceutical firm Eli Lilly, reinvested in a round set to accelerate development of Abbisko's cancer-focused drug candidates.

GV, MRL Ventures Fund and WuXi Healthcare Ventures participated in a series B round that lifted the small molecule therapy developer's overall funding to $120m.

Takeda Digital Ventures, Humana, McKesson Ventures and dRx Capital backed the online pharmacy platform developer's series B round.

Fidelity provided a $4.8m second tranche after a first close featuring KNC, Ohar Pharmaceutical, Spera Pharma, Kisco and SRD Holdings.

The healthcare product provider has promoted Lizzie Lee to lead portfolio development and market research at its corporate venturing unit.

IP Group was among the investors for UPenn-founded cancer immunotherapy developer Carisma Therapeutics, which has now raised nearly $109m altogether.

The endocrine disease drug developer completed a series B round that included $125m from former parent company Ascendis.

Sanofi Ventures contributed to a series C round for Dice Molecules, which is advancing a potential psoriasis treatment.

Livzon Pharmaceutical, Merck & Co and AbbVie helped the immuno-oncology therapy developer take its overall funding to $109m.

Taiho Ventures returned for a $72m series B round closed by Werewolf Therapeutics, which is now set to advance two lead oncology assets through phase 1 trials.